HC Wainwright Analysts Lower Earnings Estimates for NMRA

Nov 15, 2024 · Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Neumora Therapeutics in a …

CouponFollow Extension

$1.48
OFF

HC Wainwright Issues Pessimistic Forecast For NMRA Earnings

2 days from now

Nov 16, 2024 · The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2024 …

defenseworld.net

$0.45
OFF

Neumora Therapeutics’ (NMRA) Outperform Rating ... - Defense …

2 days from now

2 days ago · The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the company posted …

defenseworld.net

$1.48
OFF

What Is HC Wainwright’s Estimate For NMRA FY2024 Earnings?

2 days from now

Nov 17, 2024 · The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2024 …

etfdailynews.com

$66.15
OFF

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals

2 days from now

2 days ago · Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $66.15, accompanied by a high estimate of $80.00 and a …

benzinga.com

$64
OFF

Breaking Down Halozyme Therapeutics: 10 Analysts Share Their …

2 days from now

Nov 20, 2024 · Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $64.0, a high estimate of $73.00, and a low estimate of $52.00.

benzinga.com

$1.29
OFF

FY2024 Earnings Estimate For Novavax Issued By HC Wainwright

2 days from now

Nov 18, 2024 · HC Wainwright analyst V. Bernardino now expects that the biopharmaceutical company will earn ($1.29) per share for the year, down from their previous forecast of ($0.84). …

marketbeat.com

$7
OFF

What Analysts Are Saying About Rockwell Medical Stock

2 days from now

2 days ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.5, a high estimate of $9.00, and a low estimate of $5.00.

benzinga.com

$10.00
OFF

HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target To $10.00

2 days from now

3 days ago · HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.63) EPS, […]

defenseworld.net

$2.51
OFF

HC Wainwright Expects Lower Earnings For Zevra Therapeutics

2 days from now

5 days ago · HC Wainwright analyst O. Livnat now expects that the company will earn $2.51 per share for the year, down from their prior forecast of $2.71. HC Wainwright has a "Buy" rating …

marketbeat.com